BR112012024480A8 - Uso de fitocanabinóides canabidivarina (cbdv) no tratamento da epilepsia - Google Patents
Uso de fitocanabinóides canabidivarina (cbdv) no tratamento da epilepsiaInfo
- Publication number
- BR112012024480A8 BR112012024480A8 BR112012024480A BR112012024480A BR112012024480A8 BR 112012024480 A8 BR112012024480 A8 BR 112012024480A8 BR 112012024480 A BR112012024480 A BR 112012024480A BR 112012024480 A BR112012024480 A BR 112012024480A BR 112012024480 A8 BR112012024480 A8 BR 112012024480A8
- Authority
- BR
- Brazil
- Prior art keywords
- cbdv
- cannabidivarin
- epilepsy
- treatment
- phytocanabinoid
- Prior art date
Links
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 title abstract 5
- 206010015037 epilepsy Diseases 0.000 title abstract 3
- ZROLHBHDLIHEMS-HUUCEWRRSA-N (6ar,10ar)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 abstract 2
- ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 abstract 2
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 abstract 2
- 239000001961 anticonvulsive agent Substances 0.000 abstract 2
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 abstract 2
- 229950011318 cannabidiol Drugs 0.000 abstract 2
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 abstract 2
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 abstract 2
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 abstract 2
- 230000001773 anti-convulsant effect Effects 0.000 abstract 1
- 229960003965 antiepileptics Drugs 0.000 abstract 1
- 229960002767 ethosuximide Drugs 0.000 abstract 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229960002695 phenobarbital Drugs 0.000 abstract 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 abstract 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 abstract 1
- 229940102566 valproate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
USO DO FITOCANABINÓIDE CANABIDIVARIN (CBDV) NA FABRICAÇÃO DE UM ANTICONVULSIVANTE PARA O TRATAMENTO DE EPILEPSIA E COMPOSIÇÃO Esta invenção relaciona-se ao uso do fitocanabinóid e canabidivarin (CBDV) e combinações do fitocanabinói de CBDV com tetrahidrocanabivarina (THCV) e canabidiol (CBD ) no tratamento de epilepsia. A invenção também está rel acionada ao uso do fitocanabinóide CBDV em combinação com fá rmacos antiepiléticos padrão (SAEDs). Preferivelmente o SA ED é um 10 de etosuximida, valproato ou fenobarbital.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1005364.3A GB2479153B (en) | 2010-03-30 | 2010-03-30 | The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy |
| GB1100042.9A GB2487183B (en) | 2011-01-04 | 2011-01-04 | Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy |
| PCT/GB2011/050649 WO2011121351A1 (en) | 2010-03-30 | 2011-03-30 | Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112012024480A2 BR112012024480A2 (pt) | 2016-05-31 |
| BR112012024480A8 true BR112012024480A8 (pt) | 2018-04-03 |
Family
ID=43983229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012024480A BR112012024480A8 (pt) | 2010-03-30 | 2011-03-30 | Uso de fitocanabinóides canabidivarina (cbdv) no tratamento da epilepsia |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US9125859B2 (pt) |
| EP (2) | EP2552430A1 (pt) |
| JP (1) | JP5918748B2 (pt) |
| KR (1) | KR101849703B1 (pt) |
| CN (1) | CN103025325B (pt) |
| AR (1) | AR080730A1 (pt) |
| AU (3) | AU2011234225B2 (pt) |
| BR (1) | BR112012024480A8 (pt) |
| CA (1) | CA2794620C (pt) |
| EA (1) | EA036044B1 (pt) |
| IL (1) | IL222132B (pt) |
| MX (1) | MX2012011033A (pt) |
| MY (1) | MY162129A (pt) |
| NZ (1) | NZ602925A (pt) |
| SG (2) | SG184236A1 (pt) |
| TW (1) | TWI583374B (pt) |
| WO (1) | WO2011121351A1 (pt) |
| ZA (1) | ZA201208141B (pt) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005305675B2 (en) * | 2004-11-16 | 2012-12-13 | Gw Pharma Limited | New use for cannabinoid |
| GB0425248D0 (en) | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
| GB2471523A (en) | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
| TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途 |
| GB2487183B (en) * | 2011-01-04 | 2018-10-03 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy |
| GB2514054A (en) | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| EP3552482B1 (en) * | 2013-10-29 | 2022-06-29 | Biotech Institute, LLC | Breeding, production, processing and use of specialty cannabis |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
| WO2016044370A1 (en) | 2014-09-16 | 2016-03-24 | India Globalization Capital, Inc. | Cannabinoid composition and method for treating pain |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| EP3247359A4 (en) * | 2015-01-25 | 2018-08-08 | India Globalization Capital, Inc. | Composition and method for treating seizure disorders |
| US10238745B2 (en) | 2015-01-31 | 2019-03-26 | Constance Therapeutics, Inc. | Cannabinoid composition and products including α-tocopherol |
| CA2974292C (en) | 2015-01-31 | 2024-04-16 | Constance Therapeutics, Inc. | Methods for preparation of cannabis oil extracts and compositions |
| WO2016138505A1 (en) | 2015-02-27 | 2016-09-01 | Ebbu, LLC | Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral |
| EP3288592A4 (en) * | 2015-04-28 | 2019-01-09 | The Regents of The University of California | USE OF CANNABIDIOL FOR THE TREATMENT OF CHILDREN'S SPAS |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| WO2017027651A1 (en) | 2015-08-12 | 2017-02-16 | India Globalization Capital, Inc. | Method and composition for treating cachexia and eating disorders |
| AU2016359160A1 (en) | 2015-11-24 | 2018-06-14 | Constance Therapeutics, Inc. | Cannabis oil compositions and methods for preparation thereof |
| GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
| GB2549278B (en) * | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Use of cannabidivarin in the treatment of autism spectrum disorder |
| US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
| US10399920B2 (en) | 2016-06-01 | 2019-09-03 | S&B Pharma, Inc. | Crystalline form of cannabidiol |
| US10053407B2 (en) | 2016-06-01 | 2018-08-21 | S&B Pharma, Inc. | Crystalline cannabidivarin |
| CA3027862A1 (en) | 2016-06-15 | 2017-12-21 | India Globalization Capital, Inc. | Method and composition for treating seizure disorders |
| CN109475586A (zh) | 2016-06-29 | 2019-03-15 | 康纳塞斯创新公司 | 脱羧的大麻树脂、其用途和制备其的方法 |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| IL296008B1 (en) | 2016-08-03 | 2024-05-01 | Zelira Therapeutics Operations Pty Ltd | Cannabis compound |
| GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
| CA3034004C (en) | 2016-08-29 | 2021-08-03 | Canopy Growth Corporation | Water soluble compositions comprising purified cannabinoids |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| CN108236608B (zh) * | 2016-12-27 | 2020-05-08 | 汉义生物科技（北京）有限公司 | 大麻二酚与氨己烯酸的药物组合物及其用途 |
| CN108245499B (zh) * | 2016-12-29 | 2020-11-20 | 汉义生物科技（北京）有限公司 | 大麻二酚与双链脂肪酸类抗癫痫药物的组合物及其用途 |
| CN108245510B (zh) * | 2016-12-29 | 2020-11-20 | 汉义生物科技（北京）有限公司 | 大麻二酚与乙丙酰脲类抗癫痫药物的组合物及其用途 |
| CN108245517B (zh) * | 2016-12-29 | 2020-05-08 | 汉义生物科技（北京）有限公司 | 大麻二酚与拉莫三嗪的药物组合物及其用途 |
| GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| AU2018227544A1 (en) * | 2017-03-01 | 2019-08-29 | Canopy Growth Corporation | Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes |
| CN109106699A (zh) * | 2017-06-23 | 2019-01-01 | 汉义生物科技（北京）有限公司 | 一种用于治疗癫痫的药物组合物、其制备方法及用途 |
| CN109498606A (zh) | 2017-09-15 | 2019-03-22 | 汉义生物科技（北京）有限公司 | 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用 |
| WO2019113574A1 (en) * | 2017-12-08 | 2019-06-13 | Biotech Institute LLC | Propyl cannabinoid hemp plants, methods of producing and methods of using them |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| US20220015397A1 (en) * | 2018-12-10 | 2022-01-20 | Natural Extraction Systems, LLC | Compositions with novel cannabinoid and terpene profiles |
| BR112021017661A2 (pt) * | 2019-03-08 | 2021-11-16 | Univ California | Uso de compostos 8,9-di-hidrocanabidiol |
| GB201916977D0 (en) * | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannibidol-type cannabinoid compound |
| CA3163788A1 (en) | 2019-12-06 | 2021-06-10 | JLABS Beauty LLC | Topical compositions containing rose oil and cannabidiol and methods of making and using the same |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| KR102371269B1 (ko) | 2020-03-11 | 2022-03-07 | 연세대학교 산학협력단 | VEGFR-3 발현 조절을 통한 mTOR 관련 질환의 예방 또는 치료 방법 |
| AU2021276680A1 (en) | 2020-05-22 | 2023-01-19 | Ilera Derm LLC | Compositions for treating acne and dermatological conditions |
| MX2023001129A (es) | 2020-07-28 | 2023-03-27 | Impello Biosciences Inc | Metodos y composiciones para alterar metabolitos secundarios en plantas. |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| US20240009132A1 (en) * | 2020-11-16 | 2024-01-11 | Orcosa Inc. | Cannabinoids in the treatment of autism spectrum disorder |
| WO2022122904A1 (en) | 2020-12-09 | 2022-06-16 | Chanelle Mccoy Cbd Limited | A delayed-release capsule of cannabidiol |
| GB2606334A (en) | 2021-02-12 | 2022-11-09 | Gw Res Ltd | Use of cannabidivarin in the treatment of seizures associated with canine epilepsy |
| CN115583933B (zh) * | 2022-10-31 | 2024-02-06 | 暨明医药科技（苏州）有限公司 | 一种高纯度四氢大麻素同系物的制备方法 |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6403126B1 (en) | 1999-05-26 | 2002-06-11 | Websar Innovations Inc. | Cannabinoid extraction method |
| US6949582B1 (en) | 1999-05-27 | 2005-09-27 | Wallace Walter H | Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment |
| GB0103638D0 (en) * | 2001-02-14 | 2001-03-28 | Gw Pharmaceuticals Ltd | Pharmaceutical formulations |
| CZ306277B6 (cs) * | 2001-02-14 | 2016-11-09 | Gw Pharma Limited | Pumpičkou aktivovaná kapalná sprejová formulace |
| GB0202385D0 (en) | 2002-02-01 | 2002-03-20 | Gw Pharma Ltd | Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions |
| ITPD20020138A1 (it) * | 2002-05-24 | 2003-11-24 | Matteo Bevilacqua | Composizione di sostanze a base terpenica, metodo di preparazione e metodo di dispersione in ambiente della medesima. |
| DE10226494A1 (de) | 2002-06-14 | 2004-01-08 | Lts Lohmann Therapie-Systeme Ag | Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen |
| GB2392093B (en) * | 2002-08-14 | 2006-03-08 | Gw Pharma Ltd | Pharmaceutical formulations |
| CA2455129C (en) | 2002-08-14 | 2013-10-22 | Gw Pharma Limited | Improvements in the extraction of pharmaceutically active components from plant materials |
| MXPA05001567A (es) * | 2002-08-14 | 2005-04-25 | Gw Pharma Ltd | Formulaciones liquidas de canabinoides para la administracion a traves de la mucosa. |
| AU2005305675B2 (en) | 2004-11-16 | 2012-12-13 | Gw Pharma Limited | New use for cannabinoid |
| GB0425248D0 (en) | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
| TWI366460B (en) | 2005-06-16 | 2012-06-21 | Euro Celtique Sa | Cannabinoid active pharmaceutical ingredient for improved dosage forms |
| GB2434312B (en) * | 2006-01-18 | 2011-06-29 | Gw Pharma Ltd | Cannabinoid-containing plant extracts as neuroprotective agents |
| US9877928B2 (en) | 2006-05-30 | 2018-01-30 | Air Systems, Inc. | Gear drive damper |
| GB2438682A (en) * | 2006-06-01 | 2007-12-05 | Gw Pharma Ltd | New use for cannabinoids |
| US20080188461A1 (en) | 2007-02-01 | 2008-08-07 | Regents Of The University Of Michigan | Compositions and methods for detecting, preventing and treating seizures and seizure related disorders |
| GB2448535A (en) | 2007-04-19 | 2008-10-22 | Gw Pharma Ltd | New use for cannabinoid-containing plant extracts |
| GB2449691A (en) | 2007-05-31 | 2008-12-03 | Gw Pharma Ltd | A reference plant lacking medicinal active compound expression |
| GB2450753B (en) | 2007-07-06 | 2012-07-18 | Gw Pharma Ltd | New Pharmaceutical formulation |
| GB2456183A (en) | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
| GB2459637B (en) | 2008-01-21 | 2012-06-06 | Gw Pharma Ltd | New use for cannabinoids |
| LT2280687T (lt) | 2008-03-26 | 2019-08-26 | Stichting Sanammad | Kramtomosios gumos kompozicijos, apimančios kanabinoidus |
| GB2478072B (en) | 2008-06-04 | 2012-12-26 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
| GB2478074B (en) | 2008-06-04 | 2012-12-26 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
| GB2471523A (en) | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
| GB2478595B (en) | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
| TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途 |
| GB2479153B (en) | 2010-03-30 | 2014-03-19 | Gw Pharma Ltd | The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy |
| US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB201111261D0 (en) | 2011-07-01 | 2011-08-17 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders |
| US9750747B2 (en) | 2011-08-26 | 2017-09-05 | Bail-Portela & Ca, S.A. | Treatments involving eslicarbazepine acetate or eslicarbazepine |
| GB2514054A (en) * | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB2496687A (en) | 2011-11-21 | 2013-05-22 | Gw Pharma Ltd | Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells |
| US20150181924A1 (en) | 2013-10-31 | 2015-07-02 | Michael R. Llamas | Cannabidiol liquid composition for smoking |
| US10052339B2 (en) | 2014-03-21 | 2018-08-21 | Bodybio Inc. | Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids |
| CN114191420A (zh) | 2014-05-29 | 2022-03-18 | 雷迪厄斯制药公司 | 稳定的大麻素类化合物制剂 |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
-
2011
- 2011-03-15 TW TW100108735A patent/TWI583374B/zh active
- 2011-03-28 AR ARP110101014 patent/AR080730A1/es unknown
- 2011-03-30 US US13/075,873 patent/US9125859B2/en active Active
- 2011-03-30 EP EP11712658A patent/EP2552430A1/en not_active Withdrawn
- 2011-03-30 SG SG2012070793A patent/SG184236A1/en unknown
- 2011-03-30 CN CN201180026947.4A patent/CN103025325B/zh active Active
- 2011-03-30 MX MX2012011033A patent/MX2012011033A/es active IP Right Grant
- 2011-03-30 SG SG10201502480XA patent/SG10201502480XA/en unknown
- 2011-03-30 AU AU2011234225A patent/AU2011234225B2/en active Active
- 2011-03-30 JP JP2013501945A patent/JP5918748B2/ja active Active
- 2011-03-30 MY MYPI2012004222A patent/MY162129A/en unknown
- 2011-03-30 NZ NZ60292511A patent/NZ602925A/en unknown
- 2011-03-30 EP EP20194696.9A patent/EP3763361B1/en active Active
- 2011-03-30 WO PCT/GB2011/050649 patent/WO2011121351A1/en active Application Filing
- 2011-03-30 BR BR112012024480A patent/BR112012024480A8/pt not_active Application Discontinuation
- 2011-03-30 EA EA201290975A patent/EA036044B1/ru unknown
- 2011-03-30 CA CA2794620A patent/CA2794620C/en active Active
- 2011-03-30 KR KR1020127028091A patent/KR101849703B1/ko active IP Right Grant
-
2012
- 2012-09-24 IL IL222132A patent/IL222132B/en active IP Right Grant
- 2012-10-29 ZA ZA2012/08141A patent/ZA201208141B/en unknown
-
2015
- 2015-04-14 US US14/685,753 patent/US10799467B2/en active Active
-
2016
- 2016-10-11 AU AU2016244223A patent/AU2016244223A1/en not_active Abandoned
-
2018
- 2018-08-17 AU AU2018217303A patent/AU2018217303A1/en not_active Abandoned
-
2020
- 2020-09-04 US US17/012,448 patent/US12023305B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012024480A8 (pt) | Uso de fitocanabinóides canabidivarina (cbdv) no tratamento da epilepsia | |
| IL280294A (en) | A pharmaceutical preparation containing the phytocannabinoids cannabidiol (CBD) and cannabidiol (CBD) | |
| CL2013001433A1 (es) | Composicion que comprende al menos una n-acetil lactosamina, al menos un oligosacarido sialilado al menos un oligosacarido fucosilado; y su uso en la prevencion de infecciones respiratorias agudas y/o para aliviar los sintomas de dichas infecciones. | |
| CL2013001472A1 (es) | Mezcla de oligosaridos que comprende 5-70% en peso de al menos un oligosacarido n-acetilado, 5-90% en peso de al menos un galacto-oligosacarido, 2-50% en peso de al menos un oligosacarido sialilado y 5-70% en peso de al menos un oligosacarido fucosilado; producto alimenticio que la comprende; y su uso para la prevencion y reduccion del riesgo y/o reduccion de la severidad y/o reduccion de la ocurrencia de alergias en alimentos. | |
| BR112016029506A2 (pt) | canabidiol, e, método para tratamento de epilepsia resistente a tratamento. | |
| BRPI0911384A8 (pt) | Canabinóides em combinação com agentes quimioterápêuticos não canabinóides (por exemplo, agentes de alquilação ou serm) | |
| BRPI1005153A2 (pt) | composto, composição farmacêutica, uso de um composto, metodo para tratar um indivíduo que sofre de uma condição patológica ou doença e produto de combinação | |
| CL2012000620A1 (es) | Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20. | |
| CL2013001436A1 (es) | Composicion que comprende al menos una n-acetil-lactosamina, al menos un oligosacarido sialilado y al menos un oligosacarido fucosilado; y su uso para la prevencion y/o tratamiento de las condiciones de la piel y enfermedades de la piel. | |
| GB201111261D0 (en) | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders | |
| CY1115338T1 (el) | Χρηση ενος ή ενος συνδυασμου φυτο-κανναβινοειδων στην θεραπεια της επιληψιας | |
| ES2877502T8 (es) | Uso del fitocannabinoide cannabidiol (CBD) en combinación con un fármaco antiepiléptico estándar (SAED) en el tratamiento de la epilepsia | |
| CL2008000691A1 (es) | Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades. | |
| AR086398A1 (es) | Canabinoides que pueden usarse en el tratamiento del dolor neuropatico | |
| GT200900240A (es) | Estabilizacion de vitamina b12 | |
| PE20200338A1 (es) | Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil | |
| MX2017004761A (es) | Uso de cannabinoides en el tratamiento de enfermedades degenerativas del musculo esqueletico. | |
| ECSP10010661A (es) | Dronedarona para la prevención de la cardioversión | |
| CL2008001073A1 (es) | Uso de una secuencia de acido nucleico que codifica para un homologo tdr4 para obtener un tejido vegetal con contenido alterado de un componente flavonoide. | |
| BR112013033438A2 (pt) | dha e epa na redução do estresse oxidativo | |
| CL2014001581A1 (es) | Combinacion farmaceutica que comprende a) un antiepileptico seleccionado de pregabalina u oxcarbazepina y b) vitaminas seleccionadas de i) vitamina b12, ii) vitamina b1 y b12, con excepcion de metilcobalamina y benfotiamina; composicion farmaceutica; y su uso para tratar o prevenir el dolor moderado a severo; kit de partes. | |
| BR112018009502A2 (pt) | polifenóis de cacau e fibra dietética solúvel para uso no tratamento ou prevenção de distúrbios associados com um número acima do normal de granulócitos em um tecido | |
| GT200900332A (es) | Compuestos de bencensulfonamida apropiados para tratar transtornos que responden a la modulacion de receptor de dopamina d3 | |
| TH136434A (th) | การใช้งานของไฟโตแคนนาบินอยด์แคนนาบิดิวาริน (cbdv) ในการรักษาของโรคลมบ้าหมู | |
| TH136434B (th) | การใช้งานของไฟโตแคนนาบินอยด์แคนนาบิดิวาริน (cbdv) ในการรักษาของโรคลมบ้าหมู |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: GW PHARMA LIMITED (GB) , OTSUKA PHARMACEUTICAL CO. LIMITED (JP) Owner name: GW PHARMA LIMITED (GB) , OTSUKA PHARMACEUTICAL CO |
|
| B25A | Requested transfer of rights approved |
Owner name: GW PHARMA LIMITED (GB) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: GW PHARMA LIMITED (GB) |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |